Lenvatinib, Belzutifan, Lenvatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion
VHIO24002
Phase 2 small_molecule active
Quick answer
Lenvatinib, Belzutifan, Lenvatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion for Patients with localized renal cell carcinoma is a Phase 2 program (small_molecule) at Institut für biomedizinische Analytik NMR-Imaging GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Institut für biomedizinische Analytik NMR-Imaging GmbH
- Indication
- Patients with localized renal cell carcinoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active